Italian Fine Foods & Pharmaceuticals to use OptiBiotix Health’s LPLDL

Italian Fine Foods & Pharmaceuticals to use OptiBiotix Health’s LPLDL

March 6, 2018 Off By Dino Mustafić

OptiBiotix Health has bagged a deal with Italian Fine Foods & Pharmaceuticals N.T.M. S.p.A in which it allows Fine Foods an exclusive license for the production and supply of five formulations containing OptiBiotix’s LPLDL strain, in Europe.

Fine Foods is one of Europe’s largest and fastest growing providers of food supplements and pharmaceutical products, with reported $120 million revenues in 2017.

According to OptiBiotix Health, the agreement allow Fine Foods right to produce and commercialise new formulations containing OptiBiotix’s LPLDL, for glucose control, for reduction of high blood pressure, for reduction of cholesterol levels and two for the reduction of cardiovascular risk. These five OptiBiotix’s formulations will be marketed in new presentations including sachets and ‘melt in the mouth’ sticks, to their extensive European network in both the pharmaceutical and food supplement industry, OptiBiotix has noted.

Stephen O’Hara, CEO of OptiBiotix, said: “This agreement extends the range of products and presentations containing OptiBiotix’s LPLDL and creates an opportunity to access global pharmaceutical markets with an established industry supplier.”

O’Hara said praised Fine Foods’ industry experience, reputation, rapid revenue growth, and impressive client list of global customers in both the Pharmaceutical and Food Supplement sectors. “We believe our strategy of identifying and building partnerships with industry leading partners like Fine Foods, provides the best opportunity of rapidly building revenue streams, and establishing LPLDL as a leading global brand.”

Giorgio Ferraris, CEO of Fine Foods, said the deal with OptiBiotix allows his company to promote specific formulations and presentations containing the innovative OptiBiotix’s LPLDL strain to customers active in the growing market segment of Cholesterol and Blood pressure reduction, as well as Cardiovascular risk. He expressed his belief that this is a unique opportunity to expand Fine Foods’ commercial presence in the European Food Supplement industry, and has the potential to enhance our existing rate of growth over the coming years.